Art. -Nr.: HY-19542

C6 Ceramide

(Synonyms: C6-Cer; N-Hexanoylsphingosine)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.82%
CAS. Nr.: 124753-97-5
Formel: C₂₄H₄₇NO₃
Molecular Weight:397.63

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

C6 Ceramide Chemical Structure

CAS. Nr.: 124753-97-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	35 μM Compound: C6-Cer	Cytotoxicity against human A549 cells after 72 hrs by MTT test Cytotoxicity against human A549 cells after 72 hrs by MTT test	[PMID: 17081760]
MCF7	IC₅₀	12 μM Compound: C6Cer	Antiproliferative activity against human MCF7 cells after 24 hrs by trypan blue exclusion assay Antiproliferative activity against human MCF7 cells after 24 hrs by trypan blue exclusion assay	[PMID: 20851613]
SUP-T1	IC₅₀	48.01 μM Compound: C6 ceramide	Cytotoxicity against human SupT1 cells after 24 hrs by CellTiter-Blue assay Cytotoxicity against human SupT1 cells after 24 hrs by CellTiter-Blue assay	[PMID: 19171486]

In Vitro

C6 Ceramide (10 μg/mL, 48 h) enhances Trichostatin A (TSA) (HY-15144)-induced cell death, cell Apoptosis and induces a-tubulin acetylation in both CaOV3 and L3.6 cancer cells^[1].
C6 Ceramide (10 μg/mL, 12 h) disrupts HDAC6/PP1/tubulin complex, leading to the release of PP1 and AKT dephosphorylation and inhibition in CaOV3 and L3.6 cancer cells ^[1].
C6 Ceramide (10 μM, 48 h) increases the expression of miR29b and decreases the expressions of Akt3, PI3K and VEGFA in HUVECs^[2].
C6 Ceramide (3 and 10 μM, 7 days) increases the number of viable hippocampal neurons and enhances the dendritic outgrowth of neurons in vitro^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

CaOV3 and L3.6 cancer cells
Concentration:

10 μg/mL
Incubation Time:

48 h
Result:

Had almost no effect on cancer cell death alone, but markedly enhanced TSA-induced cell death in a dosedependent manner in both CaOV3 and L3.6 cells.

Western Blot Analysis^[2]

Cell Line:

HUVECs
Concentration:

10 μM
Incubation Time:

48 h
Result:

Signifcantly increased the expression of miR29b and decreased the expressions of Akt3, PI3K and VEGFA in HUVECs.

Chemical Information

CAS. Nr. 124753-97-5
Appearance Solid
Molecular Weight 397.63
Formel C₂₄H₄₇NO₃
Color White to off-white
SMILES

CCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O
Synonyms

C6-Cer; N-Hexanoylsphingosine
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All ELISACell Proliferation/Viability AssayWBCell Imaging/StainingBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Macrophage P2Y6R activation aggravates psoriatic inflammation through IL-27-mediated Th1 responses. [Abstract]

2024 Oct;14(10):4360-4377. PMID: 39525587

C6 Ceramide purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Oct;14(10):4360-4377. [Abstract]

IL-27 supernatant concentration of BMDMs stimulated by UDP and IMQ after PKC, JNK, p38, and ERK agonist (C6 Ceramide, 10 μmol/L) treatment.
Sci Total Environ

Cadmium exacerbates liver injury by remodeling ceramide metabolism: Multiomics and laboratory evidence. [Abstract]

2024 May 1:923:171405. PMID: 38432385

C6 Ceramide purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]

Cell viability of BRL-3A cells after C6 Ceramide (0-50 μM) intervention for 24 h was detected by CCK-8. Other groups were compared with 0 μM group.

C6 Ceramide purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]

The expression levels of apoptosis-related proteins in BRL-3A cells after 25 μM C6 Ceramide intervention and/or 20 μM cadmium exposure for 24 h were detected by western blotting.

C6 Ceramide purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]

C6 Ceramide (25 μM). Hoechst/PI double staining: Hoechst/PI was used to double stain and observe them under fluorescence microscope (200×). Hoechst 33342 can stain the nucleus with blue fluorescence. PI can stain necrotic cells with red fluorescence.

C6 Ceramide purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]

C6 Ceramide (25 μM). The levels of oxidative stress related indicators GSH, MDA, and SOD in BRL-3A cells.

C6 Ceramide purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 May 1:923:171405. [Abstract]

C6 Ceramide (25 μM). ROS production was detected by DCFH-DA staining (200×).
Br J Pharmacol

FGF1ΔHBS ameliorates DSS-induced ulcerative colitis by reducing neutrophil recruitment through the MAPK pathway. [Abstract]

2025 Apr 21. PMID: 40258390

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (251.49 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5149 mL

12.5745 mL

25.1490 mL

5 mM

0.5030 mL

2.5149 mL

5.0298 mL

10 mM

0.2515 mL

1.2575 mL

2.5149 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhu Q, et, al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011 Jan 27;2(1):e117. [Content Brief]

[2]. Liu L, et, al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020 Aug 3;18(1):298. [Content Brief]

[3]. Mitoma J, et al. Bipotential roles of ceramide in the growth of hippocampal neurons: promotion of cell survival and dendritic outgrowth in dose- and developmental stage-dependent manners. J Neurosci Res. 1998 Mar 15;51(6):712-22. [Content Brief]

[4]. Flowers M, et al. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Res Treat. 2012 Jun;133(2):447-58. [Content Brief]

[5]. Wilhelm R, et al. C6 Ceramide (d18:1/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma. Cancers (Basel). 2021 Jan 13;13(2):270. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5149 mL	12.5745 mL	25.1490 mL	62.8725 mL
	5 mM	0.5030 mL	2.5149 mL	5.0298 mL	12.5745 mL
	10 mM	0.2515 mL	1.2575 mL	2.5149 mL	6.2873 mL
	15 mM	0.1677 mL	0.8383 mL	1.6766 mL	4.1915 mL
	20 mM	0.1257 mL	0.6287 mL	1.2575 mL	3.1436 mL
	25 mM	0.1006 mL	0.5030 mL	1.0060 mL	2.5149 mL
	30 mM	0.0838 mL	0.4192 mL	0.8383 mL	2.0958 mL
	40 mM	0.0629 mL	0.3144 mL	0.6287 mL	1.5718 mL
	50 mM	0.0503 mL	0.2515 mL	0.5030 mL	1.2575 mL
	60 mM	0.0419 mL	0.2096 mL	0.4192 mL	1.0479 mL
	80 mM	0.0314 mL	0.1572 mL	0.3144 mL	0.7859 mL
	100 mM	0.0251 mL	0.1257 mL	0.2515 mL	0.6287 mL

Keywords

C6 Ceramide

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

C6 Ceramide

Apoptosis Compound Library

Anti-Cancer Compound Library

Lipid Compound Library

Anti-Blood Cancer Compound Library

Chemotherapy Drug Library

Cell Death Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Immunopotentiator Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) C6 Ceramide

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

C6 Ceramide

Apoptosis Compound Library

Anti-Cancer Compound Library

Lipid Compound Library

Anti-Blood Cancer Compound Library

Chemotherapy Drug Library

Cell Death Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Immunopotentiator Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) C6 Ceramide

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

C6 Ceramide Related Classifications

HY-19542 Related Classifications